PAR : AB.PA

AB Science S.A.

$0.702 EUR

$0.05 (8.33%)

Volume
0
Average Volume
314.46K
Market Capitalization
$51.42M
P/E Ratio
-17.86
Dividend Yield
0.00%
Price Target
Year High
$1.68
Year Low
$0.50
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$0.96
Company Overview

PAR

Alain Moussy

Drug Manufacturers - Specialty & Generic

Healthcare

AB.PA

40

FR

EUR

https://www.ab-science.com

33 1 47 20 00 14

N/A

N/A

Liquidity Metrics

-0.25

0.96

0.95

0.69

0.00

Sales & Valuation

$1.17M

43.80

-2.98

-11.25

-0.06

Profitability

-$0.0254

-$1.56M

-132.62%

-290.72%

6.99%

-6.35%

P/E Metrics

-17.86

-0.24

-0.24

Analyst Price Target & Rating

Strong Sell

1/5

0 Analysts

%

Financial Health Scores

-0.38

4/9

-$614K

$24.52M

$34.34M

-$8.56M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Alain Moussy Co-Founder, President, Scientific Director & Director
Stéphane C. Ledermann CEO & Chairman of the Board
Albert Ahn President of USA Operations
Alexis BERNARD Head of Veterinary Sales
Christian FASSOTTE Global Chief Medical Officer
Denis Gicquel Executive Vice-President
Harshad KULKARNI Head of Statistics
Laurent Guy Chief Financial Officer
Poll Results

No votes yet today — be the first to share your view!

About AB Science S.A. (PAR:AB.PA) Stock

AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safe ... ty and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.

Frequently Asked Questions

What is the current AB Science S.A. (AB.PA) stock price?

AB Science S.A.(PAR:AB.PA) stock price is $0.702 in the last trading session. During the trading session, AB.PA stock reached the peak price of $1.68 while $0.501 was the lowest point it dropped to. The percentage change in AB.PA stock occurred in the recent session was 8.33% while the dollar amount for the price change in AB.PA stock was $0.05.

AB.PA's industry and sector of operation?

The PAR listed AB.PA is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.

Who are the executives of AB.PA?

Alain Moussy | Co-Founder, President, Scientific Director & Director
Stéphane C. Ledermann | CEO & Chairman of the Board
Albert Ahn | President of USA Operations
Alexis BERNARD | Head of Veterinary Sales
Christian FASSOTTE | Global Chief Medical Officer

How many employees does AB.PA have?

Number of AB.PA employees currently stands at 40. AB.PA operates from 3, Avenue George V, Paris, IF 75008, FR.

Link for AB.PA official website?

Official Website of AB.PA is: https://www.ab-science.com

How do I contact AB.PA?

AB.PA could be contacted at phone #33 1 47 20 00 14 and can also be accessed through its website. AB.PA operates from 3, Avenue George V, Paris, IF 75008, FR.

How many shares of AB.PA are traded daily?

The average number of AB.PA shares traded daily for last 3 months was 314.46K.

What is the market cap of AB.PA currently?

The market value of AB.PA currently stands at $51.42M with its latest stock price at $0.702